UNSPSC 51321904: Evolocumab

Evolocumab is a monoclonal antibody medication designed for the treatment of hyperlipidemia.

UNSPSC 51321904 Evolocumab, a Commodity code, shows little relevant recent state and local procurement activity. The code represents a specific biopharmaceutical product — evolocumab, a PCSK9 inhibitor used to treat high cholesterol — yet the recent-opportunities block contains no solicitations for this drug. The posted records include opportunities for generic pharmaceuticals, naloxone, oxygen cylinders, and various medical supplies and services, but none specifically name evolocumab or monoclonal antibody therapies. One record labels a Seminole County naloxone procurement under this UNSPSC code despite the material mismatch between the code definition and what is actually being bought. Evolocumab procurement by state and local health departments, Medicaid programs, or healthcare facilities appears either not to be occurring in the tracked solicitation universe or is being tagged under different codes.

State and local governments typically source high-cost specialty pharmaceuticals through existing formulary agreements, state Medicaid pharmaceutical programs, or cooperative purchasing vehicles rather than through open competitive solicitations. When evolocumab does appear in government procurement, it is usually as a line item within larger pharmaceutical or pharmacy benefits contracts managed at the state level or embedded in managed-care agreements. The absence of dedicated RFPs, RFQs, or ITBs for evolocumab suggests that business development professionals should treat this code as inactive for direct government sales and instead focus on indirect channels — partnerships with state Medicaid agencies, managed Medicaid plans, or regional health systems that carry evolocumab formularies. Monitor state pharmaceutical board and Medicaid program publications for preferred-drug listings and rebate negotiations rather than public procurement notices.